NCT number | Conditions | Experimental arms | Control arm | Phases | Enrollment | Primary outcome measures |
---|---|---|---|---|---|---|
NCT03924869 | NSCLC (Stage I/II) | SBRT + Pembrolizumab (Anti-PD-1) | SBRT + Placebo | Phase 3 | 530 | EFS, OS |
NCT03774732 | NSCLC (Stage IIIB/IIIC/IV) | 3D-CRT/SABR + Pembrolizumab (Anti-PD-1) + Chemotherapy | Pembrolizumab (Anti-PD-1) + Chemotherapy | Phase 3 | 460 | OS |
NCT05298423 | NSCLC (Stage III) | Pembrolizumab (Anti-PD-1)/Vibostolimab Coformulation + Chemotherapy + Thoracic Radiotherapy | Chemotherapy + Thoracic Radiotherapy + Durvalumab (Anti-PD-L1) | Phase 3 | 784 | PFS, OS |
NCT03288870 | NSCLC (Stage IIIB/TNM Stage 4) | BCD-100 (Anti-PD-1) monotherapy | Docetaxel monotherapy | Phase 2 Phase 3 | 218 | OS |
NCT03150875 | NSCLC (Advanced/Metastatic) | IBI308 (Anti-PD-1) | Docetaxel | Phase 3 | 290 | OS |
NCT03922997 | NSCLC (Advanced/Metastatic) | Atezolizumab (Anti-PD-L1) | / | Phase 3 | 101 | SAER |
NCT02504372 | NSCLC (Stage IB/II-IIIA) | Pembrolizumab (Anti-PD-1) | Placebo | Phase 3 | 1177 | DFS |
NCT03285763 | NSCLC (Advanced/Metastatic) | Atezolizumab (Anti-PD-L1) | / | Phase 4 | 619 | PAEs |
NCT03949231 | HCC (Advanced) | PD1/PDL1 inhibitor hepatic artery infusion | PD1/PDL1 inhibitor vein infusion | Phase 3 | 200 | OS |
NCT04738487 | NSCLC | Pembrolizumab (Anti-PD-1) + Vibostolimab (Anti-PD-1) | Pembrolizumab (Anti-PD-1) | Phase 3 | 1246 | OS, PFS |
NCT04331626 | NSCLC (Metastatic) | Nivolumab (Anti-PD-1) + Low-dose Gemcitabine | / | Phase 4 | 50 | ORR |
NCT04205812 | NSCLC (Metastatic) | Retifanlimab (Anti-PD-1) + Chemotherapy | Placebo + Chemotherapy | Phase 3 | 530 | PFS, OS |
NCT03594747 | NSCLC (Advanced) | Tislelizumab (Anti-PD-1) + Carboplatin + Paclitaxel Tislelizumab (Anti-PD-1) + Carboplatin + Nab-Paclitaxel | Carboplatin + Paclitaxel | Phase 3 | 360 | PFS |
NCT03663205 | NSCLC (Advanced) | Tislelizumab (Anti-PD-1) + Platinum + Pemetrexed | Cisplatin/Carboplatin + Pemetrexed | Phase 3 | 334 | PFS |
NCT04702009 | NSCLC (Advanced) | Anti-PD-1/PD-L1 Antibody + Chemotherapy + Bronchoscopy-assisted Interventional Therapy | Anti-PD-1/PD-L1 Monoclonal Antibody + Chemotherapy | Phase 2 Phase 3 | 80 | ORR |
NCT03178552 | NSCLC (Unresectable/Advanced/Metastatic) | Cohort A: Alectinib 600 Milligrams (mg) Cohort B: Dose Finding Phase (DFP) Alectinib Cohort B: Dose Expansion Phase (DEP) Alectinib Cohort C: Atezolizumab (Anti-PD-1)1200Â mg Cohort D: Entrectinib 600 Milligrams (mg) Cohort E: Atezolizumab (Anti-PD-1), Vemurafenib, and Cobimetinib Cohort F: Atezolizumab (Anti-PD-1), Bevacizumab, Carboplatin, and Pemetrexed | Cohort C: Pemetrexed, Cisplatin or Carboplatin Cohort C: Gemcitabine, Cisplatin or Carboplatin | Phase 2 Phase 3 | 700 | PFS, TIR, ORR |
NCT03976375 | NSCLC (Metastatic) | Pembrolizumab (Anti-PD-1) + Lenvatinib (Anti-VEGF, Anti-FGFR, Anti-PDGFRα) Lenvatinib (Anti-VEGF, Anti-FGFR, Anti-PDGFRα) Monotherapy | Docetaxel | Phase 3 | 405 | OS, PFS |
NCT04921358 | NSCLC (Advanced/Metastatic) | Tislelizumab (Anti-PD-1) + Sitravatinib (Anti-AXL, Anti-MER, Anti-VEGFR2, Anti-tPDGFR, Anti-KIT, Anti-RET, Anti-MET, Anti-DDR2, Anti-TRKA) | Docetaxel | Phase 3 | 420 | OS, PFS |
NCT03906071 | NSCLC (Advanced/Metastatic) | Nivolumab (Anti-PD-1) + Sitravatinib (Anti-AXL, Anti-MER, Anti-VEGFR2, Anti-tPDGFR, Anti-KIT, Anti-RET, Anti-MET, Anti-DDR2, Anti-TRKA) | Docetaxel | Phase 3 | 532 | OS |
NCT03829332 | NSCLC (Metastatic) | Pembrolizumab (Anti-PD-1) + Lenvatinib (Anti-VEGF, Anti-FGFR, Anti-PDGFRα) | Pembrolizumab (Anti-PD-1) + Placebo | Phase 3 | 623 | OS, PFS |
NCT04157985 | NSCLC HCC (Advanced) | Discontinue Treatment with PD-1/PD-L1-1 inhibitor | Continue Treatment with PD-1/PD-L1 inhibitor | Phase 3 | 578 | PFS |
NCT04229355 | HCC (Unresectable/Advanced) | DEB-TACE + Sorafenib DEB-TACE + Lenvatinib (Anti-VEGF, Anti-FGFR, Anti-PDGFRα) | DEB-TACE + PD-1 inhibitor | Phase 3 | 90 | PFS |
NCT03062358 | HCC (Advanced) | Pembrolizumab (Anti-PD-1) + BSC | Placebo + BSC | Phase 3 | 454 | OS |
NCT05307926 | HCC (Recurrent) | PD-1 inhibitor | TACE | Phase 2 Phase 3 | 655 | DFS, TEAEs |
NCT03867084 | HCC | Pembrolizumab (Anti-PD-1) | Placebo | Phase 3 | 950 | RFS, OS |
NCT04167293 | HCC (Early) | SBRT + Sintilimab (Anti-PD-1) | SBRT | Phase 2 Phase 3 | 116 | PFS |
NCT04709380 | HCC (Advanced) | Radiotherapy + Toripalimab (Anti-PD-1) | Sorafenib | Phase 3 | 85 | TPP |
NCT03605706 | HCC (Advanced) | SHR-1210(Anti-PD-1) + FOLFOX4 | SHR-1210(Anti-PD-1) + Placebo | Phase 3 | 396 | OS |
NCT03713593 | HCC (Advanced) | Lenvatinib (Anti-VEGF, Anti-FGFR, Anti-PDGFRα) + Pembrolizumab (Anti-PD-1) | Lenvatinib (Anti-VEGF, Anti-FGFR, Anti-PDGFRα) + Placebo | Phase 3 | 750 | PFS, OS |
NCT03764293 | HCC (Unresectable/Advanced/Metastatic) | SHR-1210 (Anti-PD-1) + Apatinib (Anti-VEGFR2) | Sorafenib | Phase 3 | 543 | OS, PFS |
NCT05313282 | HCC (Advanced) | Hepatic Arterial Infusion combined with Apatinib (Anti-VEGFR-2) and Camrelizumab (Anti-PD-1) | Apatinib (Anti-VEGFR-2) + Camrelizumab (Anti-PD-1) | Phase 3 | 140 | PFS |
NCT03427827 | NPC (Advanced) | Camrelizumab (Anti-PD-1) | BSC | Phase 3 | 442 | FFS |
NCT04376866 | NPC (Recurrent) | CCRT + Toripalimab (Anti-PD-1) | CCRT | Phase 3 | 204 | OS |
NCT04778956 | NPC (Resectable/Recurrent) | Toripalimab (Anti-PD-1) + Salvage Surgery | Salvage Surgery | Phase 3 | 218 | DFS |
NCT04453813 | NPC (Recurrent) | Toripalimab (Anti-PD-1) + Concurrent Chemoradiotherapy | Concurrent Chemoradiotherapy | Phase 3 | 226 | PFS |
NCT03907826 | NPC (Recurrent) | PD-1 antibody + Chemoradiotherapy (IMRT + GP) | Chemoradiotherapy (IMRT + GP) | Phase 3 | 212 | OS |
NCT04907370 | NPC (Advanced) | Toripalimab (Anti-PD-1) + Induction Chemotherapy + IMRT | Toripalimab (Anti-PD-1) + Induction Chemotherapy + CCRT | Phase 3 | 520 | FFS |
NCT04557020 | NPC (Advanced) | PD-1 antibody + Chemotherapy + IMRT | Chemotherapy + IMRT | Phase 3 | 200 | PFS |
NCT03700476 | NPC (Advanced) | Sintilimab (Anti-PD-1) + Chemotherapy + IMRT | Chemotherapy + IMRT | Phase 3 | 425 | FFS |
NCT05097209 | NPC (Advanced) | Camrelizumab (Anti-PD-1) + Chemotherapy + IMRT | Chemotherapy + IMRT | Phase 3 | 458 | PFS |
NCT05340491 | NPC (Recurrent) | Chemotherapy + IMRT | Chemotherapy + IMRT | Phase 3 | 212 | OS |
NCT04453826 | NPC (Stage IVa, Stage II-III) | Camrelizumab (Anti-PD-1) + chemoradiotherapy arm | Chemoradiotherapy alone | Phase 3 | 388 | PFS |
NCT04890522 | NPC (Metastatic) | Triprilimab (Anti-PD-1) + Cisplatin + 5-Fluorouracil | Triprilimab (Anti-PD-1) + Cisplatin + Gemcitabine | Phase 2 Phase 3 | 622 | OS, PFS |
NCT05342792 | NPC (T4N + or TanyN2-3M0) | PD-1 antibody + Metronomic Capecitabine (Chemotherapy) | Metronomic Capecitabine (Chemotherapy) | Phase 3 | 556 | FFS |
NCT02611960 | NPC (Recurrent/Metastatic) | Pembrolizumab (Anti-PD-1) | Capecitabine + Gemcitabine + Docetaxel (Chemotherapy) | Phase 3 | 233 | OS |